To investigate the potential interaction and synergy between AF and olaparib in more AF-resistant cancer cells with low mutant p53 and WT p53 protein levels (Figure S1A,B), 2D cell cultures of three NSCLC cell lines (NCI-H2228, A549 and A549.R2) and one PDAC cell line (BxPC3) were used to perform a broadly targeted titration of olaparib (1–30 μM), AF (0.5–6.5 μM), and their combination (aurola) using the Spark Cyto live-cell imaging system. The gene discussed is TP53; the disease is cancer.